Bayer
Bayer opens new $250M facility in Berkeley to launch its cell therapy products
In a significant move to address the challenges of scaling up the production of cell therapies, Bayer, through its subsidiary ...
ICER Reviews BMS’ Eliquis, J&J’s Xarelto Amidst Medicare Price Talks
As the United States embarks on a new era of drug price negotiations, the Institute for Clinical and Economic Review ...
Bayer and Hologic partner to promote contrast-enhanced mammography for breast cancer diagnosis
Bayer and Hologic have joined forces with the aim of providing enhanced breast cancer scans by combining Bayer’s imaging contrast ...
Bayer’s new CEO plans to slash management jobs as part of a major restructuring: Reuters
Bill Anderson, Bayer’s relatively new CEO, is reportedly gearing up to make substantial changes within the pharmaceutical giant, starting with ...
Bayer launches new trials for Kerendia, a potential blockbuster for heart failure
Two summers ago, Bayer introduced Kerendia (finerenone) as a treatment for chronic kidney disease (CKD) linked to type 2 diabetes. ...
Bayer Advances Parkinson’s Cell Therapy to Phase 2 Trial
A new horizon gleams for Bayer’s quest to conquer Parkinson’s disease through advanced cell therapy. In a significant revelation, the ...
Bayer Takes Swift Action with $500,000 Aid Package for Maui After Devastating Wildfires
Responding promptly to the aftermath of the destructive wildfires on Maui, pharmaceutical giant Bayer is stepping up as one of ...
Bayer discontinues the respiratory medication PEG-ADM
Bayer’s second-quarter results update revealed a significant decision: the discontinuation of adrenomedullin pegol (PEG-ADM) development, which had progressed to Phase ...
Bayer anticipates a more bleak 2023 as decreased glyphosate sales support the argument for a separation
As calls for a business separation at Bayer grow louder, the company’s weedkiller performance is providing further support for the ...
Bayer Initiates Phase III Trial of Finerenone in Adults with Type 1 Diabetes and Chronic Kidney Disease
Source – Bayer On June 22, 2023, Bayer Initiates Phase III Trial of Finerenone, Bayer announced the initiation of a ...
Inselspital at Bern University Hospital uses Bayer’s radiological AI platform
Source – Bayer Bayer’s collection of digital X-ray, MRI, and CT imaging instruments powered by artificial intelligence will be used ...
